# FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

> **NCT06402331** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fusion Pharmaceuticals Inc.** · enrollment: 110 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** FPI-2265

## Key facts

- **NCT ID:** NCT06402331
- **Lead sponsor:** Fusion Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-05
- **Primary completion:** 2026-12-23
- **Final completion:** 2031-01-23
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06402331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06402331, "FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06402331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*